ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. is expanding its immunotherapy portfolio with the purchase of Tilos Therapeutics. The deal, worth up to $773 million, gives Merck a stable of cancer therapies aimed at modulating the activity of TGFβ, a cytokine that helps dampen the immune system response. Cambridge, Massachusetts–based Tilos has developed antibodies that act on latentcy-associated peptide, a protein that envelops TGFβ. The strategy both prevents the release of TGFβ and targets certain key cells for deletion from the tumor microenvironment.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter